BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 19349489)

  • 1. KRAS mutations in non-small cell lung cancer.
    Riely GJ; Marks J; Pao W
    Proc Am Thorac Soc; 2009 Apr; 6(2):201-5. PubMed ID: 19349489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS mutations in lung cancer.
    Karachaliou N; Mayo C; Costa C; Magrí I; Gimenez-Capitan A; Molina-Vila MA; Rosell R
    Clin Lung Cancer; 2013 May; 14(3):205-14. PubMed ID: 23122493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutation: should we test for it, and does it matter?
    Roberts PJ; Stinchcombe TE
    J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [KRAS and epidermal growth factor receptor gene mutation in non-small cell lung cancer].
    Hu W; Hu Y; Zhou K; Wang YB; Xia ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Sep; 34(9):669-72. PubMed ID: 22177492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
    Wang S; Wang Z
    Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
    Kurtze I; Sonnemann J; Beck JF
    Oncol Rep; 2011 Apr; 25(4):1021-9. PubMed ID: 21271222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis.
    Han C; Ma J; Zhao J; Zhou Y; Jing W; Zou H
    Cancer Invest; 2011 Nov; 29(9):626-34. PubMed ID: 22011285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.
    Bozzetti C; Naldi N; Nizzoli R; Azzoni C; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Gasparro D; Majori M; De Filippo M; Ardizzoni A
    Lung Cancer; 2013 Apr; 80(1):35-8. PubMed ID: 23352033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
    Takeda M; Okamoto I; Fujita Y; Arao T; Ito H; Fukuoka M; Nishio K; Nakagawa K
    J Thorac Oncol; 2010 Mar; 5(3):399-400. PubMed ID: 20186026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II
    Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
    Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
    Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.
    Martin P; Leighl NB; Tsao MS; Shepherd FA
    J Thorac Oncol; 2013 May; 8(5):530-42. PubMed ID: 23524403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers.
    Wei H; Lu W; Li M; Zhang Q; Lu S
    Yonsei Med J; 2016 Jan; 57(1):50-7. PubMed ID: 26632382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
    Zhu CQ; da Cunha Santos G; Ding K; Sakurada A; Cutz JC; Liu N; Zhang T; Marrano P; Whitehead M; Squire JA; Kamel-Reid S; Seymour L; Shepherd FA; Tsao MS;
    J Clin Oncol; 2008 Sep; 26(26):4268-75. PubMed ID: 18626007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer.
    Tímár J
    Curr Opin Oncol; 2014 Mar; 26(2):138-44. PubMed ID: 24463346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer--genetic predictors.
    Koudelakova V; Kneblova M; Trojanec R; Drabek J; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):125-36. PubMed ID: 23733083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.